Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Post-Mkt 03-20 18:54:56 EDT

10.48

-1.01

-8.79%

盘后10.92

+0.44+4.20%

18:04 EDT

High11.53	Low10.44	Vol1.53M
Open11.36	D1 Closing11.49	Amplitude9.44%
Mkt Cap327.92M	Tradable Cap164.46M	Total Shares31.29M
T/O16.34M	T/O Rate9.74%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":10.48,"timestamp":1774036800000,"preClose":11.49,"halted":0,"volume":1528944,"hourTrading":{"tag":"盘后","latestPrice":10.92,"preClose":10.48,"latestTime":"18:04 EDT","volume":200136,"amount":2096649.753,"timestamp":1774044242374,"change":0.44,"changeRate":0.041985,"amplitude":0.059857},"delay":0,"changeRate":-0.0879025239338555,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"Post-Mkt","change":-1.01,"latestTime":"03-20 18:54:56 EDT","open":11.36,"high":11.525,"low":10.44,"amount":16338631.95168,"amplitude":0.09443,"askPrice":11.87,"askSize":180,"bidPrice":10.5,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774051200000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":11.49,"preHourTrading":{"tag":"盘前","latestPrice":11.39,"preClose":11.49,"latestTime":"09:29 EDT","volume":4476,"amount":51298.27224,"timestamp":1774013399999,"change":-0.1,"changeRate":-0.008703,"amplitude":0.033072},"postHourTrading":{"tag":"盘后","latestPrice":10.92,"preClose":10.48,"latestTime":"18:04 EDT","volume":200136,"amount":2096649.753,"timestamp":1774044242374,"change":0.44,"changeRate":0.041985,"amplitude":0.059857},"volumeRatio":1.727819,"impliedVol":0.907,"impliedVolPercentile":0.542},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2621752968","title":"Eterna Therapeutics Faces Nasdaq Delisting Risk After Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752968?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:36","pubTimestamp":1774042618,"startTime":"0","endTime":"0","summary":"An announcement from Eterna Therapeutics ( ($ERNA) ) is now available. On March 18, 2026, Ernexa Therapeutics Inc. received notice from Nasdaq that...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eterna-therapeutics-faces-nasdaq-delisting-risk-after-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eterna-therapeutics-faces-nasdaq-delisting-risk-after-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","NQmain","BK4007"],"gpt_icon":0},{"id":"2621754070","title":"AN2 Therapeutics Reprices Stock Options to Enhance Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754070","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754070?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:03","pubTimestamp":1774040591,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics, Inc. ( ($ANTX) ) has issued an update. On March 19, 2026, AN2 Therapeutics’ board approved a repricing of all outstanding stock o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/an2-therapeutics-reprices-stock-options-to-enhance-retention?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/an2-therapeutics-reprices-stock-options-to-enhance-retention?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2621549377","title":"Stoke Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2621549377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621549377?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:55","pubTimestamp":1774040100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/STOK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2026 16:55 ET (20:55 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2621975488","title":"Chemomab Therapeutics Sets April 28, 2026 Shareholder Meeting to Vote on Capital Increase and Governance Matters","url":"https://stock-news.laohu8.com/highlight/detail?id=2621975488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621975488?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:27","pubTimestamp":1774038462,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics ( ($CMMB) ) has issued an update. Chemomab Therapeutics has called its Annual General Meeting of shareholders for April 28, 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-sets-april-28-2026-shareholder-meeting-to-vote-on-capital-increase-and-governance-matters?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-sets-april-28-2026-shareholder-meeting-to-vote-on-capital-increase-and-governance-matters?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2621579753","title":"Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2621579753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621579753?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:55","pubTimestamp":1774025714,"startTime":"0","endTime":"0","summary":"Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Marker Therapeutics and keeping the price target at $10.00. Patrick Trucch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/advancing-multi-antigen-cell-therapies-buy-rating-on-marker-therapeutics-ahead-of-key-2q26-fda-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/advancing-multi-antigen-cell-therapies-buy-rating-on-marker-therapeutics-ahead-of-key-2q26-fda-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LENZ"],"gpt_icon":0},{"id":"2621796758","title":"Allergy Therapeutics Deepens Real-World Data on Grassmuno® With New GRASS Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796758","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621796758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:32","pubTimestamp":1774024341,"startTime":"0","endTime":"0","summary":"Allergy Therapeutics ($GB:AGY) announced an update on their ongoing clinical study. The GRASS (Grass MATA MPL Real-world Assessment Study) is a pro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allergy-therapeutics-deepens-real-world-data-on-grassmuno-with-new-grass-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allergy-therapeutics-deepens-real-world-data-on-grassmuno-with-new-grass-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2621758706","title":"Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621758706","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621758706?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:30","pubTimestamp":1774024236,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc ($SYRE) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. (SYRE) has completed a Phase 1 trial ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-completes-first-in-human-study-of-spy001-001-de-risking-early-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-completes-first-in-human-study-of-spy001-001-de-risking-early-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539","SYRE"],"gpt_icon":0},{"id":"2621588907","title":"Knight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2621588907","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621588907?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:50","pubTimestamp":1774021834,"startTime":"0","endTime":"0","summary":"RBC Capital raised the firm’s price target on Knight Therapeutics (KHTRF) to C$8.50 from C$8 and keeps an Outperform rating on the shares. Publishe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/knight-therapeutics-price-target-raised-to-c8-50-from-c8-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/knight-therapeutics-price-target-raised-to-c8-50-from-c8-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2621935755","title":"Investor Outlook: Knight Therapeutics beats estimates on product growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2621935755","media":"Bloomberg","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621935755?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:28","pubTimestamp":1774020480,"startTime":"0","endTime":"0","summary":"Knight Therapeutics beats expectations as CEO highlights product launches and cautious outlook tied to early-stage growth across key markets.","market":"us","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/TAHQIFI2HRIIEFJT47KXPFIA74.jpg?smart=true&auth=adadeb8787fbd5b7357f87efef303fa4c3782416a98c9c6cbc9f9fea2bbbf2b6&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/TAHQIFI2HRIIEFJT47KXPFIA74.jpg?smart=true&auth=adadeb8787fbd5b7357f87efef303fa4c3782416a98c9c6cbc9f9fea2bbbf2b6&width=500&height=333"],"rights":{"source":"bnn_bloomberg_highlight","url":"https://www.bnnbloomberg.ca/investing/investor-outlook/2026/03/20/investor-outlook-knight-therapeutics-beats-estimates-on-product-growth/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/investing/investor-outlook/2026/03/20/investor-outlook-knight-therapeutics-beats-estimates-on-product-growth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2620113731","title":"Oppenheimer Adjusts Pelthos Therapeutics Price Target to $62 From $60, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620113731","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620113731?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:42","pubTimestamp":1774014159,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. (PTHS) has an average rating of Buy and mean price target of $58.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","OPY"],"gpt_icon":0},{"id":"2620733954","title":"Aquestive Therapeutics Announces Key Legal Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2620733954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620733954?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:57","pubTimestamp":1774007871,"startTime":"0","endTime":"0","summary":"Aquestive Therapeutics ( ($AQST) ) just unveiled an announcement. On March 16, 2026, Aquestive Therapeutics agreed that longtime Chief Legal Office...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aquestive-therapeutics-announces-key-legal-leadership-transition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aquestive-therapeutics-announces-key-legal-leadership-transition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2620800527","title":"LENZ Therapeutics Inc  expected to post a loss of 97 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620800527","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620800527?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:18","pubTimestamp":1774005486,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics Inc  expected to post a loss of97cents a share - Earnings Preview LENZ Therapeutics Inc LENZ.OQ LENZ.O is expected to  show a rise in quarterly revenue when it reports  results on Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2620380738","title":"Stoke Therapeutics price target raised to $60 from $36 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2620380738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620380738?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:17","pubTimestamp":1774005449,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $60 from $36 and keeps a Buy rating on the shares. The firm believes conse...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-price-target-raised-to-60-from-36-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-price-target-raised-to-60-from-36-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"1121796113","title":"Novartis to Acquire Synnovation Therapeutics Breast Cancer Drug Assets for Up to $3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1121796113","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121796113?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:02","pubTimestamp":1774004550,"startTime":"0","endTime":"0","summary":"Novartis AG has agreed to acquire an experimental breast cancer drug from Synnovation Therapeutics for up to $3 billion, aiming to strengthen its oncology product pipeline. According to a statement...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","BK4007","BK4539","LU0211331839.USD","BK4588","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4585","BK4532","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4578","NVS","LU0208291251.USD","IE00BFTCPJ56.SGD","LENZ","IE00BJT1NW94.SGD","LU0320765489.SGD","IE0009355771.USD","BK4139"],"gpt_icon":0},{"id":"2620780623","title":"Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780623","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780623?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:00","pubTimestamp":1774004400,"startTime":"0","endTime":"0","summary":"-- Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal. Officer and Chief Compliance Officer effective April 2, 2026. -- Lori J. Braender to remain in a non-executive role as Corporate Secretary. after nearly eight years as Chief Legal Officer, Chief Compliance Officer. Mr. Zalewski joins Aquestive as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026. Mr. Zalewski is a Partner at Day Pitney LLP, where he serves as Chair of the firm's Healthcare and Life Sciences practice. He has considerable experience advising life sciences, technology, and healthcare companies on a broad range of strategic and commercial matters, including mergers and acquisitions, licensing and intellectual property transactions, corporate governance, and regulatory matters. Mr. Zalewski has also served as outside general counsel to emerging and middle-market companie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4232","BK4539","AQST","BK4139","BK4007","BK4099","BK4555","BK4588","CDMO","LENZ","BK4585","BK4604","BK4022","R","TM"],"gpt_icon":0},{"id":"2620780397","title":"PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780397","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780397?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:55","pubTimestamp":1774004116,"startTime":"0","endTime":"0","summary":"David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on PYC Therapeutics Limited. The associated price target was raised to A$...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pyc-therapeutics-strengthened-balance-sheet-and-expanded-development-plan-underpin-continued-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pyc-therapeutics-strengthened-balance-sheet-and-expanded-development-plan-underpin-continued-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2620827127","title":"Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2620827127","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620827127?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:15","pubTimestamp":1774001741,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that it has entered into an agreement with Synnovation Therapeutics to acquire SNV4818, a pan-mutant-selective PI3Kalpha i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-to-acquire-pikavation-therapeutics-from-synnovation-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-to-acquire-pikavation-therapeutics-from-synnovation-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","IE0002141913.USD","BK4007","LU0208291251.USD","IE00BJT1NW94.SGD","BK4532","NVS","BK4588","IE0009355771.USD","LU0070302665.USD","BK4539","IE00BJJMRZ35.SGD","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4578","BK4139","IE00B2B36J28.USD","BK4585","LU0211331839.USD"],"gpt_icon":0},{"id":"2620207715","title":"Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2620207715","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620207715?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:00","pubTimestamp":1773986436,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics (OVID) has disclosed a new risk, in the Taxation & Government Incentives category. Ovid Therapeutics faces heightened regulatory ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-timing-risks-mount-for-ovid-therapeutics-as-fda-funding-and-staffing-volatility-threaten-drug-approval-timelines?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-timing-risks-mount-for-ovid-therapeutics-as-fda-funding-and-staffing-volatility-threaten-drug-approval-timelines?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","BK4539","BK4139","LABU","LENZ","BK4585","OVID"],"gpt_icon":0},{"id":"2620024002","title":"Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2620024002","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620024002?lang=en_us&edition=fundamental","pubTime":"2026-03-20 13:35","pubTimestamp":1773984919,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Damora Therapeutics yesterday and set a price target of $45.00. Sam Slutsky has give...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/damora-therapeutics-buy-rating-on-differentiated-calr-pipeline-clear-regulatory-path-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/damora-therapeutics-buy-rating-on-differentiated-calr-pipeline-clear-regulatory-path-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2620276758","title":"Press Release: Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276758?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:10","pubTimestamp":1773951000,"startTime":"0","endTime":"0","summary":"-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 --. -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 --. BOSTON, March 19, 2026  -- Damora Therapeutics, Inc.   , a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights.\"At Damora Therapeutics, we strive to rapidly bring forward best-in-class medicines to dramatically improve the lives of patients with blood disorders. Today, we are well on the path to achieving our goal based on recent progress, including the acquisition of three highly innovative mutant calreticulin  targeted therapies and two oversubscribed financings extending our cash runway into Phase 3 developm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443622.USD","LU2237443465.HKD","LU1363072403.SGD","BK4006","BK4226","BK4139","IE00BFXG1179.USD","LU2237443382.USD","IE00BHPRN162.USD","BK4590","ET","LU0267386448.USD","LU0882574139.USD","IE00BKVL7J92.USD","LU0170899867.USD","LU2746668974.SGD","BK4539","CMC","BK4561","LU2746668461.USD","XELA","BK4585","BK4588","LU0149725797.USD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU2237443978.SGD","BK4007","BK4144","LU2237443895.HKD","IE00B1BXHZ80.USD","LENZ","BK4581","DMRA","LU2237443549.SGD","BK4106"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.1189},{"period":"3month","weight":-0.3617},{"period":"6month","weight":-0.7282},{"period":"1year","weight":-0.5498},{"period":"ytd","weight":-0.2819}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.108722},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}